DFE Pharma expands its inhalation portfolio with the launch of Lactohale 400

Published: 5-Jul-2022

Being a leader in dry powder inhalation, DFE Pharma further expands its broad excipient portfolio of inhalation grade lactose

DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, announces the expansion of its dry powder inhalation (DPI) portfolio with the launch of Lactohale 400.

The addition of Lactohale 400 further enhances the completeness of DFE Pharma’s portfolio of inhalation grade lactose. As the whole Lactohale brand, this new grade can be customised to meet any specific need of pharmaceutical companies and can be developed jointly with formulators to ensure exactly the right outcomes for patients.

The comprehensive range of lactose-based excipients by DFE Pharma, is designed to offer the right characteristics for the full variety of inhaled medicines in the market.

For those therapies in development, DFE Pharma works together with R&D teams of pharmaceutical companies, to find the most appropriate formulation for each molecule and device combination.

Lactohale 400 is a milled, anhydrous lactose grade, that can be used in DPI applications where a relatively good flow with some cohesiveness is required.

The anhydrous nature of Lactohale 400 differentiates it from the most commonly used lactose carriers in DPI formulations. It can provide a different aerosolisation performance than lactose monohydrate with the same particle size.

“As codevelopers of DPI, DFE Pharma has a long heritage and great expertise in excipients for inhalation, while we continuously innovate in new premium solutions for inhaled therapies,” said Martti Hedman, CEO of DFE Pharma.

“With Lactohale 400, DFE Pharma expands its comprehensive lactose-based portfolio, designed to offer optimised excipients to match the increasing range of inhalant devices, each with different performance characteristics.”

You may also like